Abatacept

Title: Abatacept
CAS Registry Number: 332348-12-6
Additional Names: 1-25-Oncostatin M (human precursor) fusion protein with CTLA-4 (antigen)(human) fusion protein with immunoglobulin G1 (human heavy chain fragment); CTLA-4Ig
Manufacturers' Codes: BMS-188667
Trademarks: Orencia (BMS)
Literature References: Selective costimulation modulator that inhibits T cell activation via the CD28/B7 receptor pathway. Recombinant chimeric fusion protein composed of the extracellular domain of human cytotoxic lymphocyte-associated antigen 4 (CTLA-4) fused to the heavy constant region of human IgG. Prepn: P. S. Linsley et al., J. Exp. Med. 174, 561 (1991); eidem, WO 9300431; eidem, US 5434131 (1993, 1995 both to Bristol-Myers Squibb). CE and HPLC analysis: K. F. Greve et al., J. Chromatogr. A 723, 273 (1996). Pharmacokinetics: N. R. Srinivas et al., J. Pharm. Sci. 85, 1 (1996). Clinical evaluation in psoriasis: J. R. Abrams et al., J. Clin. Invest. 103, 1243 (1999); in rheumatoid arthritis (RA): J. M. Kremer et al., Arthritis Rheum. 52, 2263 (2005); M. C. Genovese et al., N. Engl. J. Med. 353, 1114 (2005). Review of pharmacology: N. Najafian, M. H. Sayegh, Expert Opin. Invest. Drugs 9, 2147-2157 (2000); of mechanism of action and clinical development in RA: G. G. Teng et al., Expert Opin. Biol. Ther. 5, 1245-1254 (2005).
Therap-Cat: Immunosuppressant; antipsoriatic.
Keywords: Immunosuppressant; Antipsoriatic.
Abciximab Abecarnil Abetimus Sodium Abietic Acid Abikoviromycin

Abatacept
Clinical data
Trade names Orencia
AHFS/Drugs.com monograph
MedlinePlus a606016
Pregnancy cat. C (U.S.)
Legal status POM (UK), ℞-only (U.S.)
Routes Intravenous
Pharmacokinetic data
Half-life 13.1 days
Identifiers
CAS number 213252-14-3 N
ATC code L04AA24
DrugBank DB01281
UNII 7D0YB67S97 YesY
KEGG D03203 N
ChEMBL CHEMBL1201823 N
Chemical data
Formula  ?
 N (what is this?)  (verify)

Abatacept (marketed as Orencia) is a fusion protein composed of the Fc region of the immunoglobulin IgG1 fused to the extracellular domain of CTLA-4. It is a molecule capable of binding with more avidity to CD80 (B7-1) than to CD86 (B7-2). Abatacept is a selective co-stimulation modulator as it inhibits the costimulation of T cells. It was developed by Bristol-Myers Squibb and is licensed in the United States for the treatment of rheumatoid arthritis in the case of inadequate response to anti-TNFα therapy.